Wall Street analysts predict that Proteon Therapeutics, Inc. (NASDAQ:PRTO) will post earnings per share of ($0.45) for the current quarter, Zacks reports. Zero analysts have made estimates for Proteon Therapeutics’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.55). Proteon Therapeutics reported earnings per share of ($0.43) in the same quarter last year, which indicates a negative year-over-year growth rate of 4.7%. The company is expected to issue its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that Proteon Therapeutics will report full year earnings of ($1.68) per share for the current financial year, with EPS estimates ranging from ($1.95) to ($1.47). For the next financial year, analysts forecast that the firm will post earnings of ($1.51) per share, with EPS estimates ranging from ($1.87) to ($1.00). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Proteon Therapeutics.

Proteon Therapeutics (NASDAQ:PRTO) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.11.

PRTO has been the subject of several recent research reports. Zacks Investment Research downgraded Proteon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 17th. Maxim Group set a $6.00 price objective on Proteon Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. HC Wainwright set a $2.00 price objective on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday. Finally, Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $8.00.

WARNING: This piece of content was reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.baseball-news-blog.com/2017/08/19/404037-updated.html.

Shares of Proteon Therapeutics (NASDAQ:PRTO) remained flat at $1.30 on Friday. 26,845 shares of the stock traded hands. The firm’s market capitalization is $21.80 million. Proteon Therapeutics has a one year low of $1.10 and a one year high of $11.45. The firm’s 50-day moving average is $1.38 and its 200 day moving average is $1.57.

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Get a free copy of the Zacks research report on Proteon Therapeutics (PRTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply